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  Socio-economic relevance 
Heart failure (HF) is a global health problem, it affects 26 million people worldwide 1. In total 
27.7% of deaths were attributed to HF in 2015, which has increased over the years 2.  The 
diagnosis HF impacts the lives of patients and their relatives and friends. The quality of life 
of these patients is poor and the disease controls their daily activities 3. Next to the physical 
boundaries they experience, the mental impact is also significant. At the moment, these 
patients are treated with drugs that only affect the symptoms, but will not cure the disease, 
such as angiotensin-converting enzyme inhibitors, beta blockers and diuretics 4. 
Unfortunately, the fatality rate after hospitalization for HF is 42% in 5 years, which is still 
extremely high 2. There are no other treatment options and therefore we have to invest 
money and time to find new therapies that can help these patients. Such new therapies may 
improve the quality of life, increase the life expectancy, and even prevent the development 
of HF.  
Next to the impact on the patient’s life, there is a huge economic burden that co-exists with 
HF. Due to an ageing population, the prevalence of HF will increase which will result in a 
tremendous cost for society 1,2. Especially the costs for treating HF comorbidities and HF 
symptoms in youths are significant 2,5. Therefore finding new therapies that will save lives, 
decrease care costs and help patients to improve quality of life will lower this burden.  
To find new therapies, we have to understand the pathophysiology of heart failure and all its 
different symptoms and co-morbidities. In this thesis we aim to add small pieces to a big 
puzzle that represents cellular mechanisms involved in the development of HF. We 
investigated relatively new molecules, called non-coding RNAs (ncRNAs), that turn out to be 
important mediators of pathophysiology in different disease models of HF, and are also 
associated with human HF. Here we share these new findings and to show their potential, 
thereby we aim to open doors to find new ways to diagnose and treat HF.  
Target groups 
In this thesis we provide new insights in the mechanisms underlying HF, by investigating 
molecular mechanisms involved in several etiologies that can cause HF. Understanding 
which molecules are involved in cellular signaling pathways that underlie the heart’s 
responses to pressure overload, viral myocarditis and metabolic-induced HF, improves basic 
knowledge of cell biology. The scientific community will benefit by improving awareness and 
by increased motivation to study these ncRNA molecules. In addition, the new functional 
roles of ncRNAs that we identified in this thesis might be applicable to cross scientific 
borders to other disciplines, such as cancer biology, neuroscience and liver metabolism. 
This has already been proven for miR-200c, Neat1 and Malat1 that all play a role in cancer 
biology 6–8.  
Besides the scientific community, pharmaceutical companies are an important target group 
for this thesis; they invest in developing new drugs, including ncRNA-based therapies. 
Several attempts have been made to be able to deliver ncRNA therapy at the right place in 
the human body, such as antagomiRs. GapmeRs, siRNAs, and AAV9-based viruses 9. 
Recently, the first clinical trial has been launched using siRNAs against a specific long 
ncRNA in patients with thymoma and autoimmune disease (NCT02948855; Clinical trial 
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database from US National Library of Medicine). In addition, we provide new insights in the 
role of ncRNAs that potentially can be used for future drug development.  
In general, public institutes such as the NWO (Nederlandse Organisatie voor 
Wetenschappelijk Onderzoek) and the Netherlands Heart Foundation can profit from the 
data observed in this thesis. Based on the research results we share, one can actively 
discuss what the focus of cardiac research should be, and where investments need to be 
made.  
Activities, products and innovations 
This thesis presents basic research results that improve the knowledge of basic cell 
cardiology, as well as, deeper understanding of the pathophysiology of HF. Translating 
these results to clinical practice is the main goal, however still distant. This thesis is only a 
tip of the iceberg, many more efforts have to be made to explore this disease and to get a 
better understanding of the molecular and cellular processes involved in the development of 
HF. This thesis provides a piece of the big puzzle, and thereby may stimulate other 
researchers and other research areas to investigate ncRNAs. Moreover, we used several 
techniques to manipulate ncRNA levels in vitro and in vivo, using AAV9-based vectors, 
genetic knock-out models and synthetic oligos. These techniques need further development 
to assure limited side effects before they can be introduced into the clinic, but have great 
potential.  
Cutting edge and innovative research is necessary to evolve and find new therapies. In this 
thesis we are the first to show that a small microRNA (miR-200c) is able to change the 
composition and activity status of a big protein such as titin (Chapter 6). In addition, we 
present long non-coding RNA Neat1 as a new player in the development of cardiac disease. 
Genetically depleted Neat1 mice are protected from cardiac hypertrophic remodeling and 
failure (Chapter 4). Finally, a synthetic oligo named s-mascRNA, shows the potential to 
inhibit viral replication in cardiac myocytes (Chapter 5). This proves the importance of 
ncRNA molecules for future drug development.  
Planning and realization  
To be able to translate the findings in this thesis to the clinic will be the main goal and 
challenge of the future. Upcoming studies have to prove the possibility and applicability of 
using oligo-based tools to change the levels of ncRNAs and alter outcome. In addition, 
investigating the mode of actions of these molecules in the heart is crucial to be able to 
understand exactly what is happening in a pathophysiological condition such as HF.  
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